216.73.217.151===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'harp'---select * from `0-usmeigara` WHERE code='harp'
aaハープーン　セラピューティクス

harp
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
臨床段階の免疫療法会社であるHarpoon Therapeutics、Inc。は、米国の癌や他の疾患に苦しむ患者を治療するために体の免疫系の力を活用するT細胞エンガーの新規クラスの開発に従事しています。同社は、小細胞肺がんや他のデルタ様カノニカルノッチリガンド3発現腫瘍の治療のためのフェーズI/II臨床試験にあるHPN328を含む、TRI特異的T細胞活性化コンストラクト（TRITAC）製品候補を開発しています。
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.」